Trade Hikma Pharmaceuticals PLC - HIK CFD

Hikma Company profile

Discover the latest Hikma share price today with our comprehensive live chart.

Hikma Pharmaceuticals plc. (HIK) creates and sells generic pharmaceutical solutions and products in the USA, North Africa, Europe, and the Middle East; with its headquarters located in London, UK. The company has operations in more than 50 countries and divides its work into three business units: Branded, Injectables, and Generics.

Hikma owns 29 manufacturing plants in 11 countries: Jordan, Saudi Arabia, Algeria, Egypt, Morocco, Tunisia, Sudan, United States, Portugal, Italy and Germany. The Hikma’s branded division offers 499 products in 1,256 dosage strength. The most popular products are: Amoclan, Omnisef, Blopress and Suprax. The injectables division vendors 200 products in 379 dosage forms.

Hikma pharmaceuticals share price is set and traded on the London Stock Exchange (LSE) under the ticker symbol HIK. The company constitutes the FTSE 100 and FTSE 350 Indices.

Hikma made an initial public offering on 11 November 2005, and Hikma pharmaceuticals shares were listed for the first time, raising gross proceeds of $124 million.

Hikma Pharmaceuticals was founded in Amman, Jordan, by Samih Darwazah in 1978. In August 1996, it became the first Arab company to export pharmaceutical products to the US.

The company’s biggest acquisitions include Jazeera Pharmaceutical, Saudi Arabia; Instituto Biochimico Pavese Pharma, Italy; Baxter International, US; Ribosepharm, Germany; Promopharm, Morocco, and Alkan Pharma, Egypt. All of these strategic acquisitions helped Hikma to establish itself as the world’s leading provider in its industry.

In May 2014, Hikma Pharmaceuticals plc significantly increased its presence in the injected medicine market by purchasing assets from the US generic injectable drugs business of Germany's Boehringer Ingelheim for up to $300 million.

The most recent company acquisition was Roxane Laboratories in Columbus, US. It has majorly improved Hikma's position in a non-injectables business in the US market.

Hikma has been recognised as the Company of the Year by the Global Generics and Biosimilars Awards for four years in a row: from 2014 to 2017. 

According to Hikma’s latest earnings report, the company delivered strong growth in revenue and profit in 2019 with a group core revenue of $2,203 million (up 6 per cent) and operating profit of $508 million (up 10 per cent).

Follow the Hikma share price today with Capital.com to spot the best trading opportunities. Track all the ups and downs of the HIK stock price and stay on top of the latest price fluctuations with our live Hikma stock chart.